Modulating the cleavage and polyadenylation site: from research tools to therapeutic opportunities
- 1Graduate Program in Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
- 2Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
- 3Genome Regulation and Cell Signaling Program, Ellen and Ronald Caplan Cancer Center, and Center for Systems and Computational Biology, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA
- Corresponding author: btian{at}wistar.org
Abstract
Almost all protein-coding and long noncoding genes that are transcribed by RNA polymerase II employ cleavage and polyadenylation (CPA) for 3′ end maturation of their nascent RNAs. More than 70% of human mRNA genes display alternative polyadenylation (APA), resulting in expression of isoforms using different CPA sites (also known as poly(A) sites or PAS). APA isoforms often have distinct mRNA metabolism and/or contain variable coding sequences. PAS mutations and genetic variations have been implicated in a growing number of human pathological conditions, underscoring the importance of PAS for proper gene expression. Here we review approaches that modulate the usage of specific PAS and discuss some of their applications in the context of human diseases. We provide our perspectives on current challenges and future directions of strategies of PAS modulation for studying APA isoforms and perturbing gene expression as a therapeutic modality.
Keywords
- 3′ end processing
- antisense oligonucleotides
- CRISPR
- U7 snRNP
- alternative polyadenylation
- genetic diseases
This article, published in RNA, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.
